A · API
API
Synthetic route design, substance production, impurity control and DMF preparation.
PHZAPPA · DEVELOPMENT SYSTEM
API · FINISHED FORMS · FOOD PRODUCTS
One step to the molecule, a second to the product
Contract development and manufacturing of active pharmaceutical ingredients, finished dosage forms and food products — with a meticulous approach to creating or designing around intellectual property.
PHZAPPA · ONE STEP · 2026
- 3
- production verticals
- RF·EAPO
- patent jurisdictions, extendable worldwide
- GMP
- quality benchmark
- IP
- at the initial analysis we propose paths to protect or design around
We work with highly qualified partners across all areas — from synthesis to regulatory filings.
01Company
A lab, manufacturing and patent expertise in one team.
PHZAPPA combines chemistry, process technology and legal strategy. We take a product from idea and substance synthesis through to a validated form and a registration dossier — while building the patent perimeter that strengthens the client’s market position.
- ChemistrySynthetic routes, substance production, impurity control.
- TechnologyFormulation and dosage form, scale-up, validation and site transfer.
- LawPatent landscape, filings, design-around and defence of the client’s position.
02Capabilities
Development and manufacturing of API, dosage forms and food products
We build a full production cycle for the final product that does not depend on regulatory policy: every production stage is held as the client’s intellectual property.
B · FDF
Finished dosage forms
Practically every available dosage form, tailored to your site.
C · FOOD
Food products
Functional ingredients and nutraceuticals: recipes, safety, stability, originality.
03IP Strategy
Every project leaves behind an asset, not just a product
We deliberately create intellectual property — patents related to the substance, composition or technology — so the client gains a defensible market position.
- IP·1Patent landscapingFreedom-to-operate (patent clearance) analysis and white-space search before development starts.
- IP·2RF & EAPO filingsDrafting and prosecution of applications in national and Eurasian jurisdictions, plus international filings with follow-up prosecution in any chosen country.
- IP·3Position defenseOffice-action responses and support in third-party infringement disputes, designing around or challenging patents.
“Without deviation from the norm, progress is not possible.”
04Process
Development and patenting process
A transparent route — from first brief to rights transfer and scale-up.
-
Brief & landscape
Goals, patent search and patent-clearance assessment.
-
Development
Substance synthesis and formulation, analytics and stability.
-
Patenting
Filings on synthesis technologies, composition and other position-strengthening features and technologies in RF and EAPO.
-
Scale & transfer
Production, validation and transfer of rights to the client.
05For investors
Open to investment on both horizons
The company is ready to attract investment both into expanding its own CDMO capacity and into drug development — generic and original.
INV · 1
CDMO expansion
Investment into in-house manufacturing and laboratory capacity across all verticals.
INV · 2
Drug development
The investor becomes the principal beneficiary, while we take on every stage of development and registration.
INV · 3
Ready portfolios
We have already assembled several investment portfolios that we are ready to offer to investors.
Confidential
Portfolio disclosed on request
Active projects and candidates are under NDA. Pipeline contents and readiness stages are shared with partners and investors after a confidentiality agreement is signed.
Request access06Contact
Get in touch
Tell us about the task — we’ll respond on development, manufacturing and patent options.
Write to us
contact@phzappa.comDescribe the task: molecule or product, stage, the work you need and timing. We reply within one business day.
- OfficeMoscow, Presnenskaya Emb., 12
- JurisdictionsRF · EAPO · CIS
- ScopeCDMO + patent strategy